... is certain: there,s no place like home. , Now, a ... finds the same is as true for rats as ... roam freely, most form distinct neighborhoods where they spend the ... Md., has many lively neighborhoods--each with its own personality. But ...
... J. Bartness, Regents, Professor of Biology at Georgia State ... National Institutes of Health to further research into the ... Extend Research in Time (MERIT) award from the National ... for his lab,s investigation into the communication loop between ...
... ejaculation can be embarrassing, but a new study suggests ... from Turku, Finland, interviewed more than three thousand men ... or younger brothers - about the first time they ... they had suffered from erectile dysfunction and premature ejaculation ...
Other Biology News:City rats loyal to their 'hoods, scientists discover 2Researcher garners major award from NIH for further exploration into the mechanisms of obesity 2(Date:12/11/2009)... Therapeutics, Inc., a biopharmaceutical company focused on improving ... cardiovascular and muscle disease, today announced the publication ... crucial role in the progression of amyotrophic lateral ... neuromuscular synaptic regeneration in mice. The findings, ... journal Science , reveal miR-206 as a ...
(Date:12/11/2009)... SAN DIEGO, Dec. 11 Ambit Biosciences Corporation ... of Texas M. D. Anderson Cancer Center of the ... 220 Monotherapy E fficacy) Phase 2 ... myeloid leukemia (AML). AC220 is a novel, orally ... specifically designed as a FMS-like tyrosine kinase-3 (FLT3) inhibitor. ...
(Date:12/11/2009)... Dec. 11 Gwathmey, Inc., a ... in cancer, staph aureus, and cardiovascular disease announces ... announced today that Rosalie Dunn, Ph.D., has joined ... has over 28 years of experience working with ... to joining Gwathmey, Dr. Dunn managed multimillion dollar ...
(Date:12/10/2009)... -- Dendreon Corporation (Nasdaq: DNDN ) announced today ... 15,000,000 shares of its common stock at a price ... also granted to the underwriters a 30-day option to ... stock to cover overallotments, if any. The offering ... to customary closing conditions. ,, J. P. Morgan Securities ...
Breaking Biology Technology:miRagen announces discovery of key microRNA implicated in Lou Gehrig's disease 2Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 2Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 3Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 4Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 5Rosalie Dunn, Ph.D., Joins Gwathmey, Inc. as Chief Executive Officer 2Dendreon Announces Pricing of Common Stock Offering 2Dendreon Announces Pricing of Common Stock Offering 3